| Bioactivity | Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM)[1][2][3][4]. |
| Target | B cell maturation antigens, BCMA |
| Invitro | Pavurutamab (0-10000 pM；48 h) 诱导 CD69+、CD25+ T 细胞活化和 IFNγ、TNFα、IL-2、IL-4、IL-6、IL-10 细胞因子分泌[5]。 |
| In Vivo | Pavurutamab (0.02、0.2 和 2 mg/kg；静脉注射；第 3、8、13 天单剂量) 在小鼠异种移植模型中以时间和剂量依赖的方式减少肿瘤体积[5]。Pavurutamab (0.005、0.05 和 0.5 mg/kg；静脉注射；每 5 天给药 6 次，持续 30 天) 在移植 L-363 多发性骨髓瘤 (MM) 细胞的 NOD/SCID 小鼠中，以时间和剂量依赖的方式减少肿瘤体积并提高存活率[5]。 Animal Model: |
| Name | Pavurutamab |
| CAS | 2250292-39-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sheridan C. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol. 2021 Mar;39(3):251-254. [2]. Goldsmith SR, et al. Bispecific Antibodies for the Treatment of Multiple Myeloma. Curr Hematol Malig Rep. 2022 Dec;17(6):286-297. [3]. Cho SF, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 Sep 8;4(17):4195-4207. [4]. Harrison S J, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE®(bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM)[J]. Blood, 2020, 136: 28-29. [5]. Goldstein RL, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020 Sep 8;4(17):4180-4194. |